Candidate top five peptides according to the binding-affinity of HLA-I alleles (MT IC50 and WT IC50) from three patients in HAN-high group and HAN-low group
| Gene | CDNA change | AA change | HLA allele | MT peptide | MT IC50 | WT peptide | WT IC50 | |
| HCC14 | VCX | 595G>C | Glu199Gln | HLA-A*02:06 | SQMEELPSV | 1.7 | SEMEELPSV | 23.3 |
| CHST3 | 832C>T | Arg278Trp | HLA-A*02:06 | WQLEFLQPL | 2.3 | RQLEFLQPL | 3.4 | |
| OR10G8 | 53C>T | Ala18Val | HLA-A*02:06 | FILMGLPHV | 2.4 | FILMGLPHA | 6 | |
| DYNC1H1 | 7828C>T | Arg2610Trp | HLA-A*02:06 | TLFSALWAL | 3.8 | TLFSALRAL | 129.2 | |
| CYB561D1 | 209A>T | Glu70Val | HLA-A*02:06 | WVMPVIPAL | 4.1 | WVMPEIPAL | 4.5 | |
| HCC31 | TAS2R30 | 935C>G | Thr312Arg | HLA-A*31:01 | RSLRLHRFR | 4.2 | RSLRLHRFT | 4837.8 |
| TRIM68 | 1201G>A | Gly401Arg | HLA-A*31:01 | RLRKRNEYR | 5.3 | RLRKGNEYR | 6.8 | |
| SLC4A4 | 1588G>A | Gly530Arg | HLA-A*31:01 | STRPVLVFER | 5.6 | STGPVLVFER | 93.1 | |
| ABCA2 | 1640C>T | Ser547Leu | HLA-C*03:04 | FLLPSGMAL | 5.8 | FSLPSGMAL | 2.3 | |
| GUCY1A3 | 619C>T | Pro207Ser | HLA-A*31:01 | HVYYFFSKR | 7 | HVYYFFPKR | 11.2 | |
| HCC04 | SLC26A11 | 664G>A | Val222Met | HLA-A*02:03 | LMRDHMPPV | 3.3 | LMRDHVPPV | 23.3 |
| TAS1R1 | 782G>A | Arg261His | HLA-A*02:03 | CLMHHLAQA | 3.4 | CLMRHLAQA | 4 | |
| OR7G1 | 467C>T | Ala156Val | HLA-A*02:03 | FMSTMDVLV | 4.1 | FMSTMDALV | 3.2 | |
| ADCY1 | 1975C>T | Arg659Trp | HLA-A*02:03 | VLYLHITWV | 4.9 | VLYLHITRV | 4.4 | |
| OR10G8 | 53C>T | Ala18Val | HLA-A*02:03 | FILMGLPHV | 5.1 | FILMGLPHA | 200 | |
| HCC18 | XKR4 | 122G>T | Gly41Val | HLA-A*02:01 | GLAPGLPSV | 3.4 | GLAPGLPSG | 2422.8 |
| TAS2R46 | 893G>C | Arg298Thr | HLA-A*02:01 | VLWHVTYWV | 5.5 | VLWHVRYWV | 15 | |
| CSNK1A1 | 929G>A | Arg310His | HLA-A*02:01 | YMYLRQLFHI | 8.2 | YMYLRQLFRI | 18 | |
| ANKRD36C | 1205T>C | Ile402Thr | HLA-A*11:02 | TISKLYIPK | 9.7 | IISKLYIPK | 15.7 | |
| SYNPO | 2769G>T | Lys923Asn | HLA-A*11:02 | QVWNPSFCFK | 10.3 | QVWKPSFCFK | 15.2 | |
| HCC28 | FOXB1 | 712T>C | Tyr238His | HLA-B*35:01 | MASGDHSAY | 2.6 | MASGDYSAY | 2.4 |
| MIF4GD | 185G>A | Arg62His | HLA-B*35:01 | MPSHCNTQY | 4.2 | MPSRCNTQY | 5.1 | |
| AP2A1 | 445G>T | Ala149Ser | HLA-C*03:03 | FASDIPRIL | 5.4 | FAADIPRIL | 3.9 | |
| SLC25A5 | 679A>G | Thr227Ala | HLA-B*35:01 | TAVAGLASY | 6 | TAVAGLTSY | 8.2 | |
| FRMD8 | 152C>G | Ser51Trp | HLA-B*35:01 | LPWLSAHEL | 12.9 | LPSLSAHEL | 26.4 | |
| HCC21 | NCOA3 | 600G>T | Leu200Phe | HLA-A*11:01 | HTFNCRMFMK | 4.5 | HTFNCRMLMK | 6.5 |
| HEATR3 | 740T>G | Leu247Arg | HLA-A*11:01 | SSMESRLLK | 5.1 | SSMESLLLK | 3.7 | |
| NPIPB15 | 1256T>C | Ile419Thr | HLA-A*11:01 | ATRINPWVEK | 10.4 | AIRINPWVEK | 22.6 | |
| NBAS | 4429G>C | Glu1477Gln | HLA-A*24:02 | FYQSVISNPF | 15.5 | FYESVISNPF | 44.8 | |
| RAG1 | 15C>A | Phe5Leu | HLA-C*12:02 | MAASLPPTL | 28 | MAASFPPTL | 20.8 |
HAN, high-affinity neoantigen; HCC, hepatocellular carcinoma.